Filter

Refine by collections

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 714 items for :

  • "neuroendocrine" x
  • Refine by access: All content x
Clear All
Mojun Zhu Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Mojun Zhu in
Google Scholar
PubMed Close
,
Karl R Sorenson Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Karl R Sorenson in
Google Scholar
PubMed Close
,
Rebecca Liu Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Rebecca Liu in
Google Scholar
PubMed Close
,
Bonnie E Gould Rothberg Smilow Cancer Hospital, Yale-New Haven Health System, New Haven, Connecticut, USA

Search for other papers by Bonnie E Gould Rothberg in
Google Scholar
PubMed Close
, and
Thorvardur R Halfdanarson Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed Close

Introduction Pancreatic neuroendocrine tumors (PNETs) are a group of heterogeneous malignancies with diverse pathological findings and clinical behaviors. With an annual incidence that is less than 1 per 100,000 ( Halfdanarson et al. 2008

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-21-0075
Volume/Issue:
Volume 28: Issue 12
Restricted access
A Mohamed Division of Hematology and Medical Oncology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by A Mohamed in
Google Scholar
PubMed Close
,
M Trybula Division of Hematology and Medical Oncology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by M Trybula in
Google Scholar
PubMed Close
,
S L Asa Department of Medicine, UH Seidman Cancer Center Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by S L Asa in
Google Scholar
PubMed Close
,
T R Halfdanarson Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA

Search for other papers by T R Halfdanarson in
Google Scholar
PubMed Close
, and
M B Sonbol Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, USA

Search for other papers by M B Sonbol in
Google Scholar
PubMed Close

Introduction Although rare, gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have seen a significant increase in annual incidence over recent decades ( Fraenkel et al. 2014 , Dasari et al. 2017 , Das & Dasari 2021 , White et

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-24-0025
Volume/Issue:
Volume 31: Issue 10
Restricted access
Sten Myrehaug Department of Radiation Oncology, University of Toronto

Search for other papers by Sten Myrehaug in
Google Scholar
PubMed Close
,
David L Chan Department of Medical Oncology, University of Sydney, Royal North Shore Hospital, Sydney, Australia

Search for other papers by David L Chan in
Google Scholar
PubMed Close
,
Victor Rodriguez-Freixinos Division of Medical Oncology, University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

Search for other papers by Victor Rodriguez-Freixinos in
Google Scholar
PubMed Close
,
Hans Chung Department of Radiation Oncology, University of Toronto

Search for other papers by Hans Chung in
Google Scholar
PubMed Close
,
Julie Hallet Department of Surgery, University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

Search for other papers by Julie Hallet in
Google Scholar
PubMed Close
,
Calvin Law Department of Surgery, University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

Search for other papers by Calvin Law in
Google Scholar
PubMed Close
,
Chirag Patel Department of Medical Imaging, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada

Search for other papers by Chirag Patel in
Google Scholar
PubMed Close
,
Laurent Milot Body and VIR Department, University Hospital Edouard Herriot, Lyon, France

Search for other papers by Laurent Milot in
Google Scholar
PubMed Close
,
John Hudson Department of Radiation Oncology, University of Toronto

Search for other papers by John Hudson in
Google Scholar
PubMed Close
,
Hanbo Chen Department of Radiation Oncology, University of Toronto

Search for other papers by Hanbo Chen in
Google Scholar
PubMed Close
, and
Simron Singh Division of Medical Oncology, University of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

Search for other papers by Simron Singh in
Google Scholar
PubMed Close

Introduction At diagnosis, 20.8% of patients with neuroendocrine tumours (NET) will present with metastatic disease, with almost 40% subsequently developing metastases during their disease trajectory; the vast majority to the liver ( Hallet

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-21-0030
Volume/Issue:
Volume 28: Issue 8
Restricted access
Andrew McDonald Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Andrew McDonald in
Google Scholar
PubMed Close
,
Vaidehi Avadhani Grady Memorial Hospital, Atlanta, Georgia, USA

Search for other papers by Vaidehi Avadhani in
Google Scholar
PubMed Close
,
Gabriela Oprea-Ilies Grady Memorial Hospital, Atlanta, Georgia, USA

Search for other papers by Gabriela Oprea-Ilies in
Google Scholar
PubMed Close
,
Katerina Zakka Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Katerina Zakka in
Google Scholar
PubMed Close
,
Gregory B Lesinski Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Gregory B Lesinski in
Google Scholar
PubMed Close
,
Olumide B Gbolahan Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Olumide B Gbolahan in
Google Scholar
PubMed Close
, and
Olatunji Alese Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Olatunji Alese in
Google Scholar
PubMed Close

Introduction Neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) system are a heterogeneous group of rare malignancies. While the incidence of NENs was relatively low, with 6.98 cases per 100,000 adults in 2012, the incidence

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-24-0046
Volume/Issue:
Volume 31: Issue 10
Restricted access
Sonia M Abuzakhm OhioHealth, Columbus, Ohio, USA

Search for other papers by Sonia M Abuzakhm in
Google Scholar
PubMed Close
,
Vineeth Sukrithan The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Vineeth Sukrithan in
Google Scholar
PubMed Close
,
Briant Fruth Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Briant Fruth in
Google Scholar
PubMed Close
,
Rui Qin Janssen Pharmaceuticals, Raritan, New Jersey, USA

Search for other papers by Rui Qin in
Google Scholar
PubMed Close
,
Jonathan Strosberg H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA

Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed Close
,
Timothy J Hobday Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Timothy J Hobday in
Google Scholar
PubMed Close
,
Thomas Semrad Tahoe Forest Cancer Center, Truckee, California, USA

Search for other papers by Thomas Semrad in
Google Scholar
PubMed Close
,
Diane Reidy-Lagunes Memorial Sloan Kettering Cancer Center, New York, New York, USA

Search for other papers by Diane Reidy-Lagunes in
Google Scholar
PubMed Close
,
Hedy Lee Kindler University of Chicago Medical Center, Chicago, Illinois, USA

Search for other papers by Hedy Lee Kindler in
Google Scholar
PubMed Close
,
George P Kim George Washington University Cancer Center, Washington, DC, USA

Search for other papers by George P Kim in
Google Scholar
PubMed Close
,
Jennifer J Knox Princess Margaret Cancer Centre, Toronto, ON, Canada

Search for other papers by Jennifer J Knox in
Google Scholar
PubMed Close
,
Andreas Kaubisch Montefiore Medical Center, Bronx, New York, USA

Search for other papers by Andreas Kaubisch in
Google Scholar
PubMed Close
,
Miguel Villalona-Calero City of Hope, Duarte, California, USA

Search for other papers by Miguel Villalona-Calero in
Google Scholar
PubMed Close
,
Helen Chen CTEP National Cancer Institute, Bethesda, Maryland, USA

Search for other papers by Helen Chen in
Google Scholar
PubMed Close
,
Charles Erlichman Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Charles Erlichman in
Google Scholar
PubMed Close
, and
Manisha H Shah The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA

Search for other papers by Manisha H Shah in
Google Scholar
PubMed Close

Introduction Neuroendocrine tumors (NETs) most frequently originate in the gastroenteropancreatic (GEP) system (55%), followed by the bronchopulmonary system (30%) ( Dasari et al. 2017 ). Low-to-intermediate grade NETs of the aerodigestive

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-22-0301
Volume/Issue:
Volume 30: Issue 11
Restricted access
Krystallenia I Alexandraki Department of Pathophysiology, Neuroendocrine Tumor Unit, Oxford Centre for Diabetes, National University of Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed Close
,
Gregory A Kaltsas Department of Pathophysiology, Neuroendocrine Tumor Unit, Oxford Centre for Diabetes, National University of Athens, Greece

Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed Close
,
Simona Grozinsky-Glasberg Department of Pathophysiology, Neuroendocrine Tumor Unit, Oxford Centre for Diabetes, National University of Athens, Greece

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed Close
,
Eleftherios Chatzellis Department of Pathophysiology, Neuroendocrine Tumor Unit, Oxford Centre for Diabetes, National University of Athens, Greece

Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed Close
, and
Ashley B Grossman Department of Pathophysiology, Neuroendocrine Tumor Unit, Oxford Centre for Diabetes, National University of Athens, Greece

Search for other papers by Ashley B Grossman in
Google Scholar
PubMed Close

Introduction Neuroendocrine neoplasms (NENs), previously named ‘carcinoid’ tumours, most frequently occur in the gastrointestinal (GI) tract (54.5%) and have been an area of ongoing interest in the field of many different disciplines including

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-15-0310
Volume/Issue:
Volume 23: Issue 1
Free access
Kjell Öberg University Hospital, Uppsala, Sweden

Search for other papers by Kjell Öberg in
Google Scholar
PubMed Close
and
Steven W J Lamberts Erasmus Medical Center, Rotterdam, The Netherlands

Search for other papers by Steven W J Lamberts in
Google Scholar
PubMed Close

Introduction Somatostatin analogues are the current mainstay treatment for acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NET). Acromegaly: background Acromegaly is a chronic metabolic disorder with an estimated

Article Type:
Review Article
DOI:
https://doi.org/10.1530/ERC-16-0151
Volume/Issue:
Volume 23: Issue 12
Free access
Mark Kidd Wren Laboratories, 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Mark Kidd in
Google Scholar
PubMed Close
,
Ignat Drozdov Wren Laboratories, 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Ignat Drozdov in
Google Scholar
PubMed Close
, and
Irvin Modlin Wren Laboratories, 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Irvin Modlin in
Google Scholar
PubMed Close

Introduction Biomarker assessment of gastroenteropancreatic neuroendocrine tumor (GEP–NET) disease has been difficult since the default is provided by a monoanalyte measurement, chromogranin A, which has well-described limitations ( Lawrence et al

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-15-0092
Volume/Issue:
Volume 22: Issue 4
Free access
Irvin M Modlin Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Irvin M Modlin in
Google Scholar
PubMed Close
,
Ignat Drozdov Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Ignat Drozdov in
Google Scholar
PubMed Close
,
Daniele Alaimo Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Daniele Alaimo in
Google Scholar
PubMed Close
,
Stephen Callahan Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Stephen Callahan in
Google Scholar
PubMed Close
,
Nancy Teixiera Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Nancy Teixiera in
Google Scholar
PubMed Close
,
Lisa Bodei Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Lisa Bodei in
Google Scholar
PubMed Close
, and
Mark Kidd Wren Laboratories 35 NE Industrial Road, Branford, Connecticut 06405, USA

Search for other papers by Mark Kidd in
Google Scholar
PubMed Close

Introduction Critical requirements for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) include methods that efficiently detect and monitor tumor behavior ( Modlin et al . 2008 a ). NETs are, however, a heterogeneous group

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-14-0190
Volume/Issue:
Volume 21: Issue 4
Free access
Mohid S Khan Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, 10th Floor, London NW3 2QG, UK

Search for other papers by Mohid S Khan in
Google Scholar
PubMed Close
and
Martyn E Caplin Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, 10th Floor, London NW3 2QG, UK

Search for other papers by Martyn E Caplin in
Google Scholar
PubMed Close

as a curative approach. Often neuroendocrine tumours (NETs) have metastases present at the time of diagnosis; therefore, curative resection is usually not possible, and when surgery is undertaken, it can be considered palliative in view of residual

Article Type:
Research Article
DOI:
https://doi.org/10.1530/ERC-10-0271
Volume/Issue:
Volume 18: Issue S1
Free access